| Filed On | Filing |
|---|---|
| 04 Aug 2026 |
Form 4: Kolbeck Roland Wilhelm, Chief Scientific Officer
Received 36,375 shares by exercise or conversion · Gave up 12,385 shares to cover exercise price or tax ($64.4K) |
| 08 Jun 2026 |
Form 4: Mehra Anand, Director
Granted 42,350 Stock Option (Right to Buy) · Granted 10,987 Restricted Stock Units · Received 11,580 shares by exercise or conversion |
| 08 Jun 2026 |
Form 4: Schiff Andrew N, Director
Granted 42,350 Stock Option (Right to Buy) · Granted 10,987 Restricted Stock Units · Received 11,580 shares by exercise or conversion |
| 08 Jun 2026 |
Form 4: Humphries William D., Director
Granted 42,350 Stock Option (Right to Buy) · Granted 10,987 Restricted Stock Units · Received 11,580 shares by exercise or conversion |
| 08 Jun 2026 |
Form 4: Molineaux Christopher P., Director
Granted 42,350 Stock Option (Right to Buy) · Granted 10,987 Restricted Stock Units · Received 11,580 shares by exercise or conversion |
| 08 Jun 2026 |
Form 4: Milano Vincent, Director
Granted 42,350 Stock Option (Right to Buy) · Granted 10,987 Restricted Stock Units · Received 11,580 shares by exercise or conversion |
| 08 Jun 2026 |
Form 4: Gowen Maxine, Director
Granted 42,350 Stock Option (Right to Buy) · Granted 10,987 Restricted Stock Units · Received 11,580 shares by exercise or conversion |
| 05 May 2026 |
Form 4: Hall Jesse Wayne, Chief Medical Officer
Received 36,375 shares by exercise or conversion · Gave up 9,330 shares to cover exercise price or tax ($41.1K) |
| 27 Apr 2026 |
Form 4: Leonard Braden Michael, 10% owner
Sold 300,000 shares ($1.36M) |
| 03 Mar 2026 |
Form 4: Balthaser Kevin, Chief Financial Officer
Received 2,375 shares by exercise or conversion · Gave up 677 shares to cover exercise price or tax ($1.94K) |
| 06 Feb 2026 |
Form 4: Walker Neal, Director
Granted 274,800 Restricted Stock Units · Granted 961,700 Employee Stock Option (Right to Buy) |
| 06 Feb 2026 |
Form 4: Davis Hugh M., Director
Granted 96,100 Restricted Stock Units · Granted 336,300 Employee Stock Option (Right to Buy) |
| 06 Feb 2026 |
Form 4: Kolbeck Roland Wilhelm, Chief Scientific Officer
Granted 95,700 Restricted Stock Units · Granted 334,900 Employee Stock Option (Right to Buy) |
| 06 Feb 2026 |
Form 4: Hall Jesse Wayne, Chief Medical Officer
Granted 98,100 Restricted Stock Units · Granted 343,300 Employee Stock Option (Right to Buy) |
| 06 Feb 2026 |
Form 4: Loerop James, Chief Business Officer
Granted 97,700 Restricted Stock Units · Granted 341,900 Employee Stock Option (Right to Buy) |
| 06 Feb 2026 |
Form 4: Balthaser Kevin, Chief Financial Officer
Granted 99,100 Restricted Stock Units · Granted 346,800 Employee Stock Option (Right to Buy) |
| 05 Feb 2026 |
Form 4: Loerop James, Chief Business Officer
Received 20,875 shares by exercise or conversion · Gave up 5,937 shares to cover exercise price or tax ($20.6K) |
| 05 Feb 2026 |
Form 4: Walker Neal, Director
Received 63,475 shares by exercise or conversion · Gave up 18,611 shares to cover exercise price or tax ($64.6K) |
| 05 Feb 2026 |
Form 4: Davis Hugh M., Director
Received 18,675 shares by exercise or conversion |
| 05 Feb 2026 |
Form 4: Balthaser Kevin, Chief Financial Officer
Received 22,025 shares by exercise or conversion · Gave up 6,449 shares to cover exercise price or tax ($22.4K) |
Loading...